Novacyt S.A. (EPA:ALNOV)

-1.55% (1Y)

Market Cap	35.77M
Revenue (ttm)	21.89M
Net Income (ttm)	-44.40M
Shares Out	70.56M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	503,186
Average Volume	255,347
Open	0.4945
Previous Close	0.4945
Day's Range	0.4720 - 0.5100
52-Week Range	0.4720 - 1.5900
Beta	0.08
RSI	32.51
Earnings Date	May 30, 2025

About Novacyt

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 237
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNOV

Financial Performance

In 2023, Novacyt's revenue was 11.58 million, a decrease of -44.97% compared to the previous year's 21.04 million. Losses were -28.29 million, 9.96% more than in 2022.

Financial numbers in GBP